Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

335 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Activation of STAT3 through combined SRC and EGFR signaling drives resistance to a mitotic kinesin inhibitor in glioblastoma.
Kenchappa RS, Dovas A, Argenziano MG, Meyer CT, Stopfer LE, Banu MA, Pereira B, Griffith J, Mohammad A, Talele S, Haddock A, Zarco N, Elmquist W, White F, Quaranta V, Sims P, Canoll P, Rosenfeld SS. Kenchappa RS, et al. Among authors: quaranta v. Cell Rep. 2022 Jun 21;39(12):110991. doi: 10.1016/j.celrep.2022.110991. Cell Rep. 2022. PMID: 35732128 Free PMC article.
Quantifying Drug Combination Synergy along Potency and Efficacy Axes.
Meyer CT, Wooten DJ, Paudel BB, Bauer J, Hardeman KN, Westover D, Lovly CM, Harris LA, Tyson DR, Quaranta V. Meyer CT, et al. Among authors: quaranta v. Cell Syst. 2019 Feb 27;8(2):97-108.e16. doi: 10.1016/j.cels.2019.01.003. Epub 2019 Feb 20. Cell Syst. 2019. PMID: 30797775 Free PMC article.
Charting the Fragmented Landscape of Drug Synergy.
Meyer CT, Wooten DJ, Lopez CF, Quaranta V. Meyer CT, et al. Among authors: quaranta v. Trends Pharmacol Sci. 2020 Apr;41(4):266-280. doi: 10.1016/j.tips.2020.01.011. Epub 2020 Feb 26. Trends Pharmacol Sci. 2020. PMID: 32113653 Free PMC article. Review.
MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses.
Taylor D, Meyer CT, Graves D, Sen R, Fu J, Tran E, Mirza B, Rodriguez G, Lang C, Feng H, Quaranta V, Wilson JT, Kim YJ, Korrer MJ. Taylor D, et al. Among authors: quaranta v. Front Immunol. 2022 Aug 19;13:936129. doi: 10.3389/fimmu.2022.936129. eCollection 2022. Front Immunol. 2022. PMID: 36059502 Free PMC article.
Expanded profiling of WD repeat domain 5 inhibitors reveals actionable strategies for the treatment of hematologic malignancies.
Meyer CT, Smith BN, Wang J, Teuscher KB, Grieb BC, Howard GC, Silver AJ, Lorey SL, Stott GM, Moore WJ, Lee T, Savona MR, Weissmiller AM, Liu Q, Quaranta V, Fesik SW, Tansey WP. Meyer CT, et al. Among authors: quaranta v. Proc Natl Acad Sci U S A. 2024 Aug 27;121(35):e2408889121. doi: 10.1073/pnas.2408889121. Epub 2024 Aug 21. Proc Natl Acad Sci U S A. 2024. PMID: 39167600
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.
Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, Nabet BY, Fujimoto J, Solis LM, Lu W, Xi Y, Cardnell RJ, Wang Q, Fabbri G, Cargill KR, Vokes NI, Ramkumar K, Zhang B, Della Corte CM, Robson P, Swisher SG, Roth JA, Glisson BS, Shames DS, Wistuba II, Wang J, Quaranta V, Minna J, Heymach JV, Byers LA. Gay CM, et al. Among authors: quaranta v. Cancer Cell. 2021 Mar 8;39(3):346-360.e7. doi: 10.1016/j.ccell.2020.12.014. Epub 2021 Jan 21. Cancer Cell. 2021. PMID: 33482121 Free PMC article.
335 results